Tekmira Provides Corporate Update and Reports 2010 Audited Results
30 mars 2011 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 30, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2010 Audited Results
28 mars 2011 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 28, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Sues Alnylam Pharmaceuticals for Repeated Misuse of Trade Secrets and Confidential Information
16 mars 2011 16h40 HE
|
Arbutus Biopharma Corporation
Complaint Also Alleges Unfair and Deceptive Trade Practices, Unjust Enrichment, Unfair Competition and False Advertising about Tekmira's Proprietary Lipid Nanoparticle (LNP) Technology
Conference...
Tekmira Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
10 mars 2011 08h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 10, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Proof of RNAi in Man Strengthens Leadership Position of Tekmira's LNP Delivery Technology
10 janv. 2011 08h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 10, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Tekmira Initiates TKM-PLK1 Phase 1 Human Clinical Trial
22 déc. 2010 08h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Dec. 22, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Pharmaceuticals to Webcast Presentation at the Piper Jaffray Health Care Conference
24 nov. 2010 08h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 24, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TSX:TKM) (Nasdaq:TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Intellectual Property Portfolio Expands With Granting of Key Patents Covering LNP Manufacturing and Mitigation of siRNA Immune Stimulation
22 nov. 2010 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TSX:TKM) (Nasdaq:TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced today...